bexarotene has been researched along with gemcitabine in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bedor, M; Bisaccia, S; Doyle, LA; Edelman, MJ; Hausner, P; Kalra, K; Kendall, J; Smith, R | 1 |
| Hermann, TW; Negro-Vilar, A; Ng, SC; Tooker, P; Yen, WC | 1 |
| Battistella, M; Sassolas, B | 1 |
| Chan, C; Counsell, N; Cowan, R; Gilson, D; Illidge, T; Morris, S; Patrick, P; Popova, B; Scarisbrick, J; Smith, P; Whittaker, S | 1 |
| Beyer, M; Erdmann, R; Humme, D; Nast, A; Vandersee, S | 1 |
| Assaf, C; Nicolay, JP | 1 |
3 review(s) available for bexarotene and gemcitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Systematic review of combination therapies for mycosis fungoides.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Deoxycytidine; Ficusin; Gemcitabine; Humans; Hydroxamic Acids; Interferon-alpha; Methotrexate; Mycosis Fungoides; Phototherapy; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Vorinostat | 2014 |
[Treatment of mycosis fungoides and Sézary syndrome].
Topics: Adrenal Cortex Hormones; Bexarotene; Brentuximab Vedotin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Immunoconjugates; Interferon-alpha; Mycosis Fungoides; Neoplasm Recurrence, Local; Neoplasm Staging; Phototherapy; Polyethylene Glycols; PUVA Therapy; Sezary Syndrome; Skin Neoplasms; World Health Organization | 2017 |
2 trial(s) available for bexarotene and gemcitabine
| Article | Year |
|---|---|
Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome | 2005 |
Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Remission Induction; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; United Kingdom | 2013 |
3 other study(ies) available for bexarotene and gemcitabine
| Article | Year |
|---|---|
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Gene Amplification; Humans; Lung Neoplasms; Mice; Mice, Nude; Retinoid X Receptors; Tetrahydronaphthalenes; Xenograft Model Antitumor Assays | 2007 |
[Therapeutic perspectives of cutaneous T-cell lymphoma].
Topics: Antineoplastic Agents; Bexarotene; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Interferons; Lymphoma, T-Cell, Cutaneous; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes | 2011 |